Company

Kodiak Sciences Inc.

Headquarters: Palo Alto, CA, United States

Employees: 93

CEO: Dr. Victor Perlroth M.D.

NASDAQ: KOD +1.90%

Market Cap

$123.5 Million

USD as of July 1, 2024

Market Cap History

Kodiak Sciences Inc. market capitalization over time

Evolution of Kodiak Sciences Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Kodiak Sciences Inc.

Detailed Description

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Kodiak Sciences Inc. has the following listings and related stock indices.


Stock: NASDAQ: KOD wb_incandescent

Stock: BMV: KOD wb_incandescent

Stock: FSX: K27 wb_incandescent

Details

Headquarters:

2631 Hanover Street

Palo Alto, CA 94304

United States

Phone: 650 281 0850